©2019 by Lexeo Therapeutics

BREAKING NEW GROUND IN GENETIC MEDICINE

Addressing many of the world's most devastating hereditary and acquired diseases with gene therapy

 

OUR STORY

Founded with a new vision for gene therapy

LEXEO Therapeutics is a New York City based clinical stage gene therapy biotechnology company with a focus on hereditary and acquired diseases of high unmet need.  Founded in 2018 based on 25 years of research at a leading scientific institution, LEXEO's investigational therapies have the potential to offer gene therapy based treatments to address many diseases that have eluded today's existing drug delivery platforms.  Our mission at LEXEO is to lead the field of gene therapy as a fully integrated biotechnology company; discovering, developing and delivering treatments and cures to some of today's most devastating diseases

 

WHAT WE DO

The possibilities are endless

To transfer therapeutic genes, LEXEO Therapeutics utilizes adeno-associated viruses (AAV) that have been engineered to transfer genes to patients.  LEXEO's Therapeutics investigational treatments include gene therapies primarily in the early clinical and late pre-clinical stages of research and development.  These treatments are designed to address diseases in the Central Nervous System, Rare/Hereditary, Inflammation, Oncology and Addiction disease areas

 
Science

We Are Ready to Bring Transformational Science to the Challenges of Today's Diseases

 

GET IN TOUCH

430 East 29th Street, 14th Floor
New York, New York

(212) 547-9879

Science